Elevating Skin Through
Medical Exosome Science
Patented MEDexomarine™ Technology
- PCT/JP2024/045706
- PCT/JP2024/045689
MEDESTHÉ is a professional cosmeceutical brand developed for in-office use and post-procedure skin care, supporting skin comfort, appearance, and quality following aesthetic interventions. Powered by MEDexomarine, a highly purified and stable marine-derived exosomes, sourced from microalgae cultivated in Okinawa, Japan, that are naturally rich in anti-inflammatory antioxidants such as phycocyanin, high levels of omega-3 fatty acids (DHA and EPA), and betaine lipids. These components help reduce dryness and osmotic stress while supporting skin balance, resilience, and recovery.
MEDESTHÉ formulations are designed to support skin balance, barrier function, and overall skin quality after procedures such as lasers, injectables, microneedling, peels, surgery, and hair restoration. All products are fragrance-free and alcohol-free, formulated for high tolerance and professional use, providing targeted cosmetic support for compromised-looking skin.
Post Injection Recovery Cream
Post Laser Tinted Recovery Balm
Post Injection Tinted Recovery Balm
Post Surgery Silicone Repair Gel
Mesolution for Dermal Quality Optimisation
Premium Mesolution for Global Age Defense
Scalp Vitalising Mesolution
Where Japanese scientific innovation meets regenerative aesthetics.
Rohto MediLuxe (RML) is the European subsidiary of Rohto Pharmaceutical, Japan’s leading innovator in health and beauty, with over 127 years of scientific excellence. Rohto Japan reported €1.7billion in sales (FY2024) and is listed on the Prime Market of the Tokyo Stock Exchange. Established in Paris in 2023, RML serves as Rohto’s strategic hub for advancing innovation, investment, and business development across the medical aesthetics and professional dermatology sectors globally.
